Hostname: page-component-8448b6f56d-dnltx Total loading time: 0 Render date: 2024-04-23T08:28:13.048Z Has data issue: false hasContentIssue false
  • English
  • Français

SPARC and Vav3 Expression in Meningioma: Factors Related to Prognosis

Published online by Cambridge University Press:  23 September 2014

Jie Jiang ,
Yuejia Song ,
Nan Liu ,
Chengjun Lin ,
Shiguang Zhao ,
Yu Sun ,
Zhen Zhang ,
Xiang Fang  and
Jiping Qi
Jie Jiang
Affiliation:
Department of Pathology, First Affiliated Hospital of Harbin Medical University, Harbin, PR China
Yuejia Song
Affiliation:
Department of Digestive System, First Affiliated Hospital of Harbin Medical University, Harbin, PR China
Nan Liu
Affiliation:
Department of Pathology, First Affiliated Hospital of Harbin Medical University, Harbin, PR China
Chengjun Lin
Affiliation:
Department of Anesthesiology, Fourth Affiliated Hospital of Harbin Medical University, Harbin, PR China
Shiguang Zhao
Affiliation:
Department of Neurosurgery, First Affiliated Hospital of Harbin Medical University, Harbin, PR China
Yu Sun
Affiliation:
Department of Pathology, First Affiliated Hospital of Harbin Medical University, Harbin, PR China
Zhen Zhang
Affiliation:
Department of Pathology, First Affiliated Hospital of Harbin Medical University, Harbin, PR China
Xiang Fang
Affiliation:
Department of Pathology, First Affiliated Hospital of Harbin Medical University, Harbin, PR China
Jiping Qi*
Affiliation:
Department of Pathology, First Affiliated Hospital of Harbin Medical University, Harbin, PR China
*
Department of Pathology, First Affiliated Hospital of Harbin Medical University, 23 Youzheng Street, Nangang District, Harbin 150001, PR China. Email: bless88775469@163.com.
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

Meningiomas account for approximately 24-30% of primary intracranial neoplasms. Histopathologic grade and degree of resection are two major prognostic factors. The aim of this study was to determine the factors associated with the prognosis of meningioma.

Methods:

We used immunohistochemistry to analyze the expression levels of Vav3, SPARC, p-Akt, cyclin D1, and Ki-67 in 287 meningiomas of all grades.

Results:

The expression of Vav3, SPARC, p-Akt, cyclin D1, and Ki- 67 significantly increased with meningioma grade (p<0.01), and was higher in brain-invasive meningiomas compared to non-invasive meningiomas (WHO grade I) (p<0.05). Furthermore, the expression of Vav3, p-Akt, and Ki-67 was higher in recurrent meningiomas compared to non-recurrent meningiomas (WHO grade I) (p<0.05).

Conclusion:

The expression of Vav3, SPARC, p-Akt, cyclin D1, and Ki-67 in meningiomas appears to correlate with meningioma invasiveness, aggressiveness, and recurrence.

Résumé

RÉSUMÉContexte:

les méningiomes constituent à peu près 24 à 30% des néoplasies intracrâniennes primitives. Le grade histopathologique et le degré de résection de la tumeur sont deux facteurs de pronostic importants. Le but de cette étude était de déterminer les facteurs associés au pronostic du méningiome.

Méthode:

nous avons utilisé l'immunohistochimie pour analyser le niveau d'expression de Vav3, SPARC, p-AKt, cycline D1 et Ki-67 dans 287 méningiomes de tout grade.

Résultats:

L'expression de Vav3, SPARC, p-Akt, cycline D1 et Ki-67 augmentait significativement avec l'augmentation du grade de la tumeur (p ˂ 0,01) et elle était plus élevée dans les méningiomes envahissants que dans les méningiomes non envahissants (OMS grade 1) (p ˂ 0,05). De plus, l'expression de Vav3, p-Akt et Ki-67 était plus élevée dans les méningiomes récurrents que dans les méningiomes non récurrents (Grade I de l'OMS) (p ˂ 0,05).

Conclusion:

L'expression de Vav3, SPARC, p-Akt, cycline D1 et Ki-67 dans les méningiomes semble corrélée au caractère invasif et agressif du méningiome ainsi qu'à sa récurrence.

Type
Original Article
Information
Canadian Journal of Neurological Sciences , Volume 40 , Issue 6 , November 2013 , pp. 814 - 818
Copyright
Copyright © The Canadian Journal of Neurological 2013

References

1. Claus, EB, Bondy, ML, Schidkraut, JM, Wiemels, JL, Wrensch, M, Black, PM. Epidemiology of intracranial meningioma. Neurosurgery. 2005;57:1088–95.CrossRefGoogle ScholarPubMed
2. Cordera, S, Bottacchi, E, D'Alessandro, G, Machado, D, De Gonda, F, Corso, G. Epidemiology of primary intracranial tumors in NW Italy, a population based study: stable incidence in the last two decades. J Neurol. 2002;249:281–4.Google Scholar
3. Perry, A, Louis, DN, Scheithauer, BW, Budka, H, von Deimling, A. Meningiomas. In: Louis DN, Ohgaki H, Wiestler OD, Cavanee W.K, editors. World Health Organization Classification of Tumours of the Central Nervous System. Lyon: IARC Press; 2007. p. 164–72.Google Scholar
4. Rempel, SA, Ge, S, Gutiérrez, JA. SPARC: A potential diagnostic marker of invasive meningiomas. Clin Cancer Res. 1999;5:237–41.Google Scholar
5. Milenkovic, S, Marinkovic, T, Jovanovic, MB, Djuricic, S, Berisavac, II, Berisavac, I. Cyclin D1 immunoreactivity in meningiomas. Cell Mol Neurobiol. 2008;28:907–13.Google Scholar
6. Dong, ZY, Liu, Y, Lu, S, et al. Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer. Mol Endocrinol. 2006;20(10):2315–25.CrossRefGoogle ScholarPubMed
7. Malik, SN, Brattain, M, Ghosh, PM, et al. Immunohistochemical demonstration of Phospho-Akt in High Gleason Grade Prostate Cancer. Clin Cancer Res. 2002;8:1168–71.Google Scholar
8. Bruna, J, Brell, M, Ferrer, I, Gimenez-Bonafe, P, Tortosa, A. Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma. Neuropathology. 2007;27:114–20.CrossRefGoogle ScholarPubMed
9. Alama, A, Barbieri, F, Spaziante, R, et al. Significance of cyclin D1 expression in meningiomas: A preliminary study. J Clin Neurosci. 2007;14:355–58.Google Scholar
10. Wong, S, Crowley, D, Bronson, R, Hynes, R. Analyses of the role of endogenous SPARC in mouse models of prostate and breast cancer. Clin Exp Metast. 2008;25:109–18.Google Scholar
11. Schittenhelm, J, Mittelbronn, M, Roser, F, Tatagiba, M, Mawrin, C, Bornemann, A. Patterns of SPARC expression and basement membrane intactness at the tumour–brain border of invasive meningiomas. Neuropath Appl Neuro. 2006;32:525–31.Google Scholar
12. Bozkurt, SU, Ayan, E, Bolukbasi, F, Elmaci, I, Pamir, N, Sav, A. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas. APMIS. 2009;117:651–59.Google Scholar
13. Seno, T, Harada, H, Kohno, S, Teraoka, M, Inoue, A, Ohnishi, T. Downregulation of SPARC expression inhibits cell migration and invasion in malignant gliomas. Int J Oncol. 2009;34:707–15.Google Scholar
14. Mawrin, C, Sasse, T, Kirches, E, et al. Different activation of mitogen-activated protein kinase and akt signaling is associated with aggressive phenotype of Human meningiomas. Clin Cancer Res. 2005;11(11):4074–82.Google Scholar
15. Lee, K, Liu, Y, Mo, JQ, Zhang, J, Dong, ZY, Lu, S. Vav3 oncogene activates estrogen receptor and its overexpression may be involved in human breast cancer. BMC Cancer. 2008;8:158.Google Scholar